CSA Medical Announces New Thermal Penetration Results for Multiple Cryogenic Sprays at DDW

BOSTON, May 10, 2016 /PRNewswire/ -- CSA Medical announced novel thermal penetration modeling and data related to its truFreeze® liquid nitrogen spray cryotherapy system in addition to those of other cryogens will be unveiled at Digestive Disease Week 2016 in San Diego, California.

CSA Medical, the leading developer of technologies used to deliver liquid nitrogen cryospray inside the body to ablate both benign and malignant tissues, will be presenting results from a Thermal Penetration study characterizing tissue temperature changes during cryogenic spray. This study is intended to provide physicians with quantitative 3-dimensional thermal profiles induced by cryogens in simulated tissue. Liquid nitrogen, the coldest of available ablative cryogens, will be compared to nitrous oxide and carbon dioxide.

"This study is an important milestone in the support of physicians using the truFreeze system to ablate tissue in the upper GI tract," explained Ellen Sheets, M.D., CEO and President of CSA Medical. "Peer-reviewed studies have been and continue to be published on the use of truFreeze in this anatomical area. This new quantitative data enables CSA Medical to further educate physicians on the thermal penetration profile of liquid nitrogen compared to those of other cryogens."

About Liquid Nitrogen

Liquid nitrogen is a powerful ablative cryogen that produces a rejuvenative response to the targeted tissue. The extreme cold of liquid nitrogen, with a usage temperature of -196°C, causes a "fast freeze" of the intracellular water inside cells. The subsequent thaw leads to destruction of vital intracellular energy-producing organelles causing cell death and reabsorption. The underlying extracellular matrix is left intact, allowing new healthy cells to propagate. Compared to heat-based ablation technologies, which are considered reparative, minimal scarring occurs at the ablation site.

About CSA Medical

CSA Medical, Inc. develops and manufactures a proprietary interventional spray cryotherapy technology platform utilizing unique properties of liquid nitrogen spray delivered by a software driven device with specialty catheters that enable delivery of spray cryogen inside the body to flash freeze and destroy unwanted tissue allowing for a rejuvenative pattern of healing. CSA manufactures and distributes this technology in the USA as the truFreeze® system which is currently used to ablate unwanted benign and malignant tissue.

To learn more about our technology, please visit www.csamedical.com.

PRLog ID: www.prlog.org/12556395

SOURCE CSA Medical

Related Links

http://www.csamedical.com